

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2008

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

000-50679

(Commission File Number)

Delaware

(State or other jurisdiction of
incorporation)

77-0487658

(I.R.S. Employer Identification No.)

149 Commonwealth Drive

Menlo Park, CA 94025

(Address of principal executive offices, with zip code)

(650) 327-3270

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01. Entry into a Material Definitive Agreement

On June 4, 2008 the Company and ICON Clinical Research, LP (ICON) completed the execution of a Master Service Agreement (MSA) under which ICON will assist the Company in various clinical trial activities, including the selection of clinical sites, supervision and monitoring of clinical site performance at various institutions and data collection and analysis in connection with Study 14, the Company's current Phase 3 trial, to confirm the utility of CORLUX for the treatment of the psychotic features of psychotic depression. According to the MSA, any project contract entered into under the MSA may be terminated by the Company at any time upon sixty days' written notice, or sooner based on the mutual agreement of the parties, or by either party based on safety concerns, an uncured breach, or insolvency of either party. Upon termination, the Company would be obligated to pay ICON for services performed and pass-through costs incurred to the date of termination plus a cancellation fee to compensate the CRO for staff reallocation costs.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORCEPT THERAPEUTICS INCORPORATED

Date: June 5, 2008

By: /s/ Anne M. LeDoux

Name: Anne M. LeDoux

Title: Vice President and Chief Accounting Officer